No Data
No Data
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
LOS ANGELES, April 29, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology,
Acelyrin Insiders Placed Bullish Bets Worth US$2.65m
Acelyrin(SLRN.US) Officer Sells US$66,024.5 in Common Stock
$Acelyrin(SLRN.US)$ Officer Lin Shao-Lee sold 9,961 shares of Common Stock on Apr 1, 2024 at an average price of $6.6283 for a total value of $66,024.5.Source: Announcement What is statement of change
Express News | HC Wainwright & Co. Reiterates Buy on Acelyrin, Maintains $28 Price Target
ACELYRIN, INC.: Promising Clinical Trials and Market Opportunity Justify Buy Rating
Express News | Acelyrin Q4 EPS $(0.75) Beats $(0.99) Estimate
No Data
diamonds : 请问,ENDPQ重组后,持有的股票还能有效吗?